Business
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Da
About this update from In8bio, Inc.
[{"type":"image","alt":"IN8bio, Inc","displaySize":"","headline":null,"caption":"IN8bio, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iE_JG4N3QKlIMRV4FlM2jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOQ--/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18","width":300,"height":149},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/iE_JG4N3QKlIMRV4FlM2jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOQ--/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18","width":300,"height":149}},"lazy":false},{"type":"text","content":"NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Day on May 21, 2026, showcasing advances across its γδ T cell pipeline, including its novel T cell engager (TCE) and clinical γδ T cell therapy programs.","length":655,"tagName":"p"},{"type":"text","content":"“We look forward to sharing progress across our γδ T cell platforms at our R&D Day and several key meetings this quarter,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “These presentations highlight the progress we are making with our novel TCE program, complemented by translational advances in our clinical program supporting the observed survival benefits in DeltEx DRI treated glioblastoma (GBM) patients. The unique properties of γδ T cells enable them to address key challenges in TCE development and to meaningfully improve outcomes in difficult-to-treat cancers.”","length":597,"tagName":"p"},{"type":"text","content":"Presentation details are outlined below:","length":40,"tagName":"p"},{"type":"text","content":"IN8bio 2026 R&D Day (New York, New York)In-person and Virtual","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Featuring presentations on o...